small cell lung cancer Archives -

News/ News/ News/ Oncology/ R&D

Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde

Phil Taylor chemotherapy, Ipsen, Oncology, Onivyde, Servier, small cell lung cancer 0 Comment

Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a

Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde

https://pharmaphorum.com/news/phase-3-lung-cancer-fail-dents-prospects-of-ipsen-serviers-onivyde/

News/ News/ Oncology

Henlius claims win for PD-1 drug in small cell lung cancer

Phil Taylor ES-SCLC, immuno-oncology, Oncology, PD-1, serplulimab, Shanghai Henlius Biotech, small cell lung cancer 0 Comment

China’s Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in

Henlius claims win for PD-1 drug in small cell lung cancer

https://pharmaphorum.com/news/henlius-claims-win-for-pd-1-drug-in-small-cell-lung-cancer/

News/ News/ Oncology

AstraZeneca bags Imfinzi okay in big Chinese lung cancer market

Phil Taylor AstraZeneca, China, Imfinzi, Roche, small cell lung cancer, Tecentriq 0 Comment

China has approved AstraZeneca’s PD-1/PD-L1 inhibitor Imfinzi to treat small-cell lung cancer (SCLC), an aggressive form of the

AstraZeneca bags Imfinzi okay in big Chinese lung cancer market

https://pharmaphorum.com/news/astrazeneca-bags-imfinzi-okay-in-big-chinese-lung-cancer-market/

Market Access/ News/ News/ News/ Oncology/ Top stories

NICE recommends Roche’s Tecentriq in ES-SCLC following price rethink

Richard Staines cancer, ES-SCLC, market access, NICE, Roche, small cell lung cancer, Tecentriq 0 Comment

NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell

NICE recommends Roche’s Tecentriq in ES-SCLC following price rethink

https://pharmaphorum.com/news/nice-recommends-roches-tecentriq-in-es-sclc-following-price-rethink/

News/ News/ Oncology

Merck & Co’s Keytruda produces mixed results in SCLC

Richard Staines Merck & Co, small cell lung cancer 0 Comment

Merck & Co’s Keytruda immunotherapy has produced mixed results in a phase 3 trial testing it in first-line

Merck & Co’s Keytruda produces mixed results in SCLC

https://pharmaphorum.com/news/merck-cos-keytruda-produces-mixed-results-in-sclc/

News/ News/ Oncology

PharmaMar and Jazz sign $1bn US deal for lung cancer drug lurbinectedin

Richard Staines cancer, Jazz Pharmaceuticals, PharmaMar, small cell lung cancer 0 Comment

Spain’s PharmaMar and Jazz Pharmaceuticals have signed a $1 billion license agreement for the lung cancer drug lurbinectedin

PharmaMar and Jazz sign $1bn US deal for lung cancer drug lurbinectedin

https://pharmaphorum.com/news/pharmamar-and-jazz-sign-1bn-us-deal-for-lung-cancer-drug/

News/ News/ News/ Oncology/ R&D

AbbVie axes multi-billion cancer flop Rova-T after another trial fails

Richard Staines AbbVie, lung cancer, small cell lung cancer 0 Comment

AbbVie has axed its troubled lung cancer drug Rova-T, after another trial failure from the drug that is

AbbVie axes multi-billion cancer flop Rova-T after another trial fails

https://pharmaphorum.com/news/abbvie-axes-multi-billion-cancer-flop-rova-t-after-another-trial-fails/

Market Access/ News/ News/ News/ R&D

Opdivo and Keytruda approved in new lung cancer uses

Piotr Wnuk Bristol-Myers Squibb, FDA approval, Opdivo, SCLC, small cell lung cancer 0 Comment

The FDA has approved Merck’s Keytruda (pembrolizumab) as a combination treatment for metastatic nonsquamous non-small cell lung cancer

Opdivo and Keytruda approved in new lung cancer uses

https://pharmaphorum.com/news/bmss-opdivo-approved-lung-cancer/

Trending

small cell lung cancer

Login